Compare TransMedics Group Inc (TMDX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vale SA — how do they compare? TransMedics Group Inc trades at $86.41 (market cap $3.10B), while Vale SA trades at $14.46 (market cap $61.97B). The key difference: Vale SA is far larger — about 20× TransMedics Group Inc's market cap, and Vale SA pays a 8.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VALE | |
|---|---|---|
Market Cap | $3.10B | $61.97B |
Sector | Technology | Basic Materials |
52-Week High | $150.42 | $17.82 |
52-Week Low | $61.99 | $9.71 |
Enterprise Value | $3.49B | $78.22B |
Dividend Yield | — | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Vale S.A. (VALE) trades at $14.89, up 1.22% today, with a neutral technical stance. The company reported Q2 2026 EPS of $0.36, missing estimates of $0.41, continuing a trend of earnings misses. Revenue for 2025 was $38.40B, with net income margin at 5.11%. Cash flow from operations remains strong at $8.80B for 2025, supporting a $0.40 dividend scheduled for payment in September 2026.
The outlook is mixed: analyst consensus price target is $16.79 (12.8% upside), but rising costs and earnings misses pose risks. Base metals growth offers opportunity, yet iron ore volatility and debt increases require monitoring. The stock presents value with a P/E of 28.64 and EV/EBITDA of 7.65, but investor caution is warranted given recent performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
